Immunome (IMNM) EBIT (2019 - 2026)
Immunome's (IMNM) quarterly EBIT came in at -$59.3 million in Q1 2026, down 32.92% YoY from -$88.5 million in Q1 2025, and up 18.57% on a QoQ basis from -$72.9 million in Q4 2025.
Immunome (IMNM) EBIT (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of EBIT data on file, last reported at -$59.3 million in Q1 2026.
- Quarterly EBIT fell 32.92% year-over-year to -$59.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$238.8 million (down 9.48% YoY) and the FY2025 annual result came in at -$224.1 million, up 26.71% from the prior year.
- EBIT grew to -$59.3 million in Q1 2026, from -$72.9 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$4.5 million in Q1 2023 to a low of -$132.3 million in Q1 2024.
- A 5-year average of -$43.3 million and a median of -$44.6 million in 2025 frame the typical range for EBIT.
- Annual changes were most pronounced in 2024 — EBIT sank 2859.05% — and 2025, when it soared 66.26%.
- Tracing IMNM's EBIT over 5 years: stood at -$7.8 million in 2022, then plunged by 1115.53% to -$94.7 million in 2023, then advanced by 12.34% to -$83.0 million in 2024, then advanced by 12.18% to -$72.9 million in 2025, then climbed by 18.57% to -$59.3 million in 2026.
- The last three EBIT figures came in at -$59.3 million (Q1 2026), -$72.9 million (Q4 2025), and -$60.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | -78.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -78.14 Mn |
| Mar 31, 2026 | -59.33 Mn |
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -60.14 Mn |
| Jun 30, 2025 | -46.48 Mn |
| Mar 31, 2025 | -44.64 Mn |
| Dec 31, 2024 | -82.97 Mn |
| Sep 30, 2024 | -50.52 Mn |
| Jun 30, 2024 | -40.01 Mn |
| Mar 31, 2024 | -132.30 Mn |
| Dec 31, 2023 | -94.65 Mn |
| Sep 30, 2023 | -4.63 Mn |
| Jun 30, 2023 | -5.77 Mn |
| Mar 31, 2023 | -4.47 Mn |
| Dec 31, 2022 | -7.79 Mn |
| Sep 30, 2022 | -8.53 Mn |
| Jun 30, 2022 | -8.93 Mn |
| Mar 31, 2022 | -11.65 Mn |
| Dec 31, 2021 | -7.84 Mn |
| Sep 30, 2021 | -7.72 Mn |